EP Patent

EP3017811A1 — Apixaban formulations

Assigned to Bristol Myers Squibb Holdings Ireland ULC · Expires 2016-05-11 · 10y expired

What this patent protects

Compositions comprising crystalline apixaban particles having a D 90 equal to or less than 89 µm, and a pharmaceutically acceptable carrier, are substantially bioequivalent and can be used to for the treatment and/or prophylaxis of thromboembolic disorders.

USPTO Abstract

Compositions comprising crystalline apixaban particles having a D 90 equal to or less than 89 µm, and a pharmaceutically acceptable carrier, are substantially bioequivalent and can be used to for the treatment and/or prophylaxis of thromboembolic disorders.

Drugs covered by this patent

Patent Metadata

Patent number
EP3017811A1
Jurisdiction
EP
Classification
—
Expires
2016-05-11
Drug substance claim
No
Drug product claim
No
Assignee
Bristol Myers Squibb Holdings Ireland ULC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.